Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

281.72
+1.540.55%
Post-market: 282.130.4100+0.15%16:59 EDT
Volume:197.40K
Turnover:55.78M
Market Cap:5.62B
PE:29.01
High:287.90
Open:284.22
Low:278.28
Close:280.18
52wk High:326.63
52wk Low:158.13
Shares:19.94M
Float Shares:19.35M
Volume Ratio:1.06
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:5.80
PE(LYR):45.96

Loading ...

Reaffirmed 2026 Guidance After Strong Q2 Could Be A Game Changer For Ligand Pharmaceuticals (LGND)

Simply Wall St.
·
Aug 19

Ligand Pharmaceuticals Price Target Announced at $330.00/Share by Leerink Partners

Dow Jones
·
Aug 15

Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio

Reuters
·
Aug 08

Ligand Pharmaceuticals Price Target Raised to $345.00/Share from $340.00 by RBC Capital

Dow Jones
·
Aug 08

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), AMN Healthcare Services (AMN) and Warby Parker (WRBY)

TIPRANKS
·
Aug 08

RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating

MT Newswires Live
·
Aug 07

Ligand Pharmaceuticals (LGND) Posts Strong Q2 Results, Is The Upside Already Priced In?

Simply Wall St.
·
Aug 07

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Ligand Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Protagonist Therapeutics (PTGX) and Zoetis (ZTS)

TIPRANKS
·
Aug 07

Ligand Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $358 from $289

THOMSON REUTERS
·
Aug 06

Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook

Reuters
·
Aug 06

Ligand Pharmaceuticals Incorporated Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed

MT Newswires Live
·
Aug 06

Agenus Q2 Revenue Rises on Access and Royalty Income

Reuters
·
Aug 06

GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $9.00 to $9.50, vs. FactSet Est of $9.21

MT Newswires Live
·
Aug 06

Ligand Q2 FY26 Adjusted EPS Climbs 48% to $2.37; Revenue Rises 34% to $63.7 Million

Reuters
·
Aug 06

Ligand Pharmaceuticals Q2 Adj. EPS $2.37 Beats $1.84 Estimate, Sales $63.693M Beat $60.765M Estimate

Benzinga Earnings
·
Aug 06

Ligand Pharmaceuticals Incorporated - 2026 Total Revenue Guidance $270 Mln to $310 Mln

THOMSON REUTERS
·
Aug 06

Ligand Pharmaceuticals Incorporated - 2026 Adj EPS Guidance $9 to $9.50, Previously $8.50 to $9.50

THOMSON REUTERS
·
Aug 06